Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Somewhere deep in my mind, the guilt starts to build as I know this will only make things infinitely worse in the long run.

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Experts said there’s no conclusive evidence that a measles infection boosts a person’s immune system later in life against cancer, heart disease or atopic diseases. Several studies show that a measles ...

Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

The only change she mentioned was, because it was frigid outside, she and her friends were going to the mall a lot where they ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

While scratching an itch can worsen skin allergies, it can also improve the body’s defense mechanism against certain ...